Efforts to promote interoperability, advance electronic prescribing of controlled substances, and ensure that technological advances in the pharmacy services sector, including in electronic prescribing, benefit patients, prescribers, and others in a timely way.
Efforts to advance interoperability and to ensure that technological advances in the pharmacy services sector, including in electronic prescribing, benefit patients, prescribers, and others in a timely way.
Duration: November 17, 2017
to
present
General Issues: Health Issues , Science/Technology , Medicare/Medicaid
Spending: about $1,040,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2017: Health & Human Services - Dept of (HHS), House of Representatives, U.S. Senate, Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, MCDERMOTT WILL & EMERY LLP lobbied for Surescripts , earning $30,000. The report was filed on April 16.
Original Filing: 301550366.xml
Lobbying Issues
Efforts to promote interoperability, advance electronic prescribing of controlled substances, and ensure that technological advances in the pharmacy services sector, including in electronic prescribing, benefit patients, prescribers, and others in a timely way.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
Lobbying Issues
Efforts to advance interoperability and to ensure that technological advances in the pharmacy services sector, including in electronic prescribing, benefit patients, prescribers, and others in a timely way.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
Type of Issue
Science/Technology/Medicaid
4th Quarter, 2023
In Q4, MCDERMOTT WILL & EMERY LLP lobbied for Surescripts , earning $40,000. The report was filed on Jan. 16.
Original Filing: 301524924.xml
Lobbying Issues
Efforts to promote interoperability, advance electronic prescribing of controlled substances, and ensure that technological advances in the pharmacy services sector, including in electronic prescribing, benefit patients, prescribers, and others in a timely way.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
Lobbying Issues
Efforts to advance interoperability and to ensure that technological advances in the pharmacy services sector, including in electronic prescribing, benefit patients, prescribers, and others in a timely way.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
Type of Issue
Science/Technology/Medicaid
3rd Quarter, 2023
In Q3, MCDERMOTT WILL & EMERY LLP lobbied for Surescripts , earning $30,000. The report was filed on Oct. 18, 2023.
Original Filing: 301504267.xml
Lobbying Issues
Efforts to advance interoperability and to ensure that technological advances in the pharmacy services sector, including in electronic prescribing, benefit patients, prescribers, and others in a timely way.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues/Technology/Medicaid
2nd Quarter, 2023
In Q2, MCDERMOTT WILL & EMERY LLP lobbied for Surescripts , earning $30,000. The report was filed on July 14, 2023.
Original Filing: 301476237.xml
Lobbying Issues
Efforts to advance interoperability and to ensure that technological advances in the pharmacy services sector, including in electronic prescribing, benefit patients, prescribers, and others in a timely way.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues/Technology/Medicaid
1st Quarter, 2023
In Q1, MCDERMOTT WILL & EMERY LLP lobbied for Surescripts , earning $40,000. The report was filed on April 14, 2023.
Original Filing: 301451667.xml
Lobbying Issues
Efforts to advance interoperability and to ensure that technological advances in electronic prescribing benefit patients, prescribers and others in the pharmacy services sector in a timely way.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues/Technology/Medicaid
4th Quarter, 2022
In Q4, MCDERMOTT WILL & EMERY LLP lobbied for Surescripts , earning $30,000. The report was filed on Jan. 13, 2023.
Original Filing: 301427182.xml
Lobbying Issues
Efforts to advance interoperability and to ensure that technological advances in electronic prescribing benefit patients, prescribers and others in the pharmacy services sector in a timely way, including efforts to advance Cures 2.0 (H.R. 6000), which would improve the process for updating the SCRIPT electronic prescribing standard to allow for more expeditious adoption of updated electronic prescribing standards.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues/Technology/Medicaid
3rd Quarter, 2022
In Q3, MCDERMOTT WILL & EMERY LLP lobbied for Surescripts , earning $40,000. The report was filed on Oct. 17, 2022.
Original Filing: 301405493.xml
Lobbying Issues
Efforts to advance interoperability and to ensure that technological advances in electronic prescribing benefit patients, prescribers and others in the pharmacy services sector in a timely way, including efforts to advance Cures 2.0 (H.R. 6000), which would improve the process for updating the SCRIPT electronic prescribing standard to allow for more expeditious adoption of updated electronic prescribing standards.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues/Technology/Medicaid
2nd Quarter, 2022
In Q2, MCDERMOTT WILL & EMERY LLP lobbied for Surescripts , earning $40,000. The report was filed on July 19, 2022.
Original Filing: 301386234.xml
Lobbying Issues
Efforts to advance interoperability and to ensure that technological advances in electronic prescribing benefit patients, prescribers and others in the pharmacy services sector in a timely way, including efforts to advance Cures 2.0 (H.R. 6000), which would improve the process for updating the SCRIPT electronic prescribing standard to allow for more expeditious adoption of updated electronic prescribing standards.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues/Technology/Medicaid
1st Quarter, 2022
In Q1, MCDERMOTT WILL & EMERY LLP lobbied for Surescripts , earning $40,000. The report was filed on April 18, 2022.
Original Filing: 301358465.xml
Lobbying Issues
Efforts to advance interoperability and to ensure that technological advances in electronic prescribing benefit patients, prescribers and others in the pharmacy services sector in a timely way, including efforts to advance Cures 2.0 (H.R. 6000), which would improve the process for updating the SCRIPT electronic prescribing standard to allow for more expeditious adoption of updated electronic prescribing standards.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues/Technology/Medicaid
4th Quarter, 2021
In Q4, MCDERMOTT WILL & EMERY LLP lobbied for Surescripts , earning $40,000. The report was filed on Jan. 11, 2022.
Original Filing: 301321203.xml
Lobbying Issues
Efforts to advance interoperability and to ensure that technological advances in electronic prescribing benefit patients, prescribers and others in the pharmacy services sector in a timely way, including efforts to advance Cures 2.0 (H.R. 6000), which would improve the process for updating the SCRIPT electronic prescribing standard to allow for more expeditious adoption of updated electronic prescribing standards.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues/Technology/Medicaid
3rd Quarter, 2021
In Q3, MCDERMOTT WILL & EMERY LLP lobbied for Surescripts , earning $40,000. The report was filed on Oct. 14, 2021.
Original Filing: 301299399.xml
Lobbying Issues
Efforts to advance interoperability and to ensure that technological advances in electronic prescribing benefit patients, prescribers and others in the pharmacy services sector in a timely way, including improving the process for updating the SCRIPT electronic prescribing standard to allow for more expeditious adoption of updated electronic prescribing standards.
Efforts to ensure timely implementation of the SUPPORT Act requirement for electronic prescribing of controlled substances (EPCS) in the Medicare Part D program and to encourage CMS to expand the use of EPCS beyond the Part D program.
Efforts to support CMS rulemaking to ensure timely advancement of the NCPDP Formulary and Benefit Standard from Version 3.0 to Version 5.0 and to ensure timely adoption of a Real-Time Benefit Tool standard as soon as one is approved by NCPDP.
Efforts to obtain clarity relating to the HIPAA Transactions Rule and Code Sets Rule to ensure that the eligibility transaction requirements do not apply to prior authorization requests for prescription drugs so that electronic prior authorization by non-Part D prescribers using the NPCPD SCRIPT Standard Version 2017071 is not impeded.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues/Technology/Medicaid
2nd Quarter, 2021
In Q2, MCDERMOTT WILL & EMERY LLP lobbied for Surescripts , earning $40,000. The report was filed on July 18, 2021.
Original Filing: 301279219.xml
Lobbying Issues
Efforts to advance interoperability and to ensure that technological advances in electronic prescribing benefit patients, prescribers and others in the pharmacy services sector in a timely way, including improving the process for updating the SCRIPT electronic prescribing standard to allow for more expeditious adoption of updated electronic prescribing standards.
Efforts to ensure timely implementation of the SUPPORT Act requirement for electronic prescribing of controlled substances (EPCS) in the Medicare Part D program and to encourage CMS to expand the use of EPCS beyond the Part D program.
Efforts to support CMS rulemaking to ensure timely advancement of the NCPDP Formulary and Benefit Standard from Version 3.0 to Version 5.0 and to ensure timely adoption of a Real-Time Benefit Tool standard as soon as one is approved by NCPDP.
Efforts to obtain clarity relating to the HIPAA Transactions Rule and Code Sets Rule to ensure that the eligibility transaction requirements do not apply to prior authorization requests for prescription drugs so that electronic prior authorization by non-Part D prescribers using the NPCPD SCRIPT Standard Version 2017071 is not impeded.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues/Technology/Medicaid
1st Quarter, 2021
In Q1, MCDERMOTT WILL & EMERY LLP lobbied for Surescripts , earning $40,000. The report was filed on April 19, 2021.
Original Filing: 301258673.xml
Lobbying Issues
Efforts to advance interoperability and to ensure that technological advances in electronic prescribing benefit patients, prescribers and others in the pharmacy services sector in a timely way, including improving the process for updating the SCRIPT electronic prescribing standard to allow for more expeditious adoption of updated electronic prescribing standards.
Efforts to ensure timely implementation of the SUPPORT Act requirement for electronic prescribing of controlled substances (EPCS) in the Medicare Part D program and to encourage CMS to expand the use of EPCS beyond the Part D program.
Efforts to support CMS rulemaking to ensure timely advancement of the NCPDP Formulary and Benefit Standard from Version 3.0 to Version 5.0 and to ensure timely adoption of a Real-Time Benefit Tool standard as soon as one is approved by NCPDP.
Efforts to obtain clarity relating to the HIPAA Transactions Rule and Code Sets Rule to ensure that the eligibility transaction requirements do not apply to prior authorization requests for prescription drugs so that electronic prior authorization by non-Part D prescribers using the NPCPD SCRIPT Standard Version 2017071 is not impeded.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues/Technology/Medicaid
4th Quarter, 2020
In Q4, MCDERMOTT WILL & EMERY LLP lobbied for Surescripts , earning $60,000. The report was filed on Jan. 19, 2021.
Original Filing: 301235333.xml
Lobbying Issues
Efforts to advance interoperability and to ensure that technological advances in electronic prescribing benefit patients, prescribers and others in the pharmacy services sector in a timely way, including improving the process for updating the SCRIPT electronic prescribing standard to allow for more expeditious adoption of updated electronic prescribing standards.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues/Technology
Lobbying Issues
Efforts to advance interoperability and to ensure that technological advances in electronic prescribing benefit patients, prescribers and others in the pharmacy services sector in a timely way, including improving the process for updating the SCRIPT electronic prescribing standard to allow for more expeditious adoption of updated electronic prescribing standards.
Efforts to ensure timely implementation of the SUPPORT Act requirement for electronic prescribing of controlled substances in the Medicare Part D program beginning January 1, 2021.
Efforts to support CMSs proposed adoption of NCPDP SCRIPT Standard Version 2017071 for secure electronic prior authorization transactions for Part D-covered drugs and to ensure that problematic preamble language in the proposed rule is addressed so that electronic prior authorization by non-Part D prescription drug plans is not impeded by the final rule.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
3rd Quarter, 2020
In Q3, MCDERMOTT WILL & EMERY LLP lobbied for Surescripts , earning $60,000. The report was filed on Oct. 18, 2020.
Original Filing: 301212765.xml
Lobbying Issues
Efforts to advance interoperability and to ensure technological advances in electronic prescribing benefit patients, prescribers and others in the pharmacy services benefits in a timely way, including improving the process for updating the SCRIPT electronic prescribing standard to allow for both testing and for more expeditious adoption of updated electronic prescribing standards.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues/Technology
Lobbying Issues
Efforts to advance interoperability and to ensure technological advances in electronic prescribing benefit patients, prescribers and others in the pharmacy services benefits in a timely way, including improving the process for updating the SCRIPT electronic prescribing standard to allow for both testing and for more expeditious adoption of updated electronic prescribing standards.
Efforts to ensure timely implementation of the SUPPORT Act requirement for electronic prescribing of controlled substances in the Medicare Part D program beginning January 1, 2021.
Efforts to support CMSs proposed adoption of NCPDP SCRIPT Standard Version 2017071 for secure electronic prior authorization transactions for Part D-covered drugs and to ensure that problematic preamble language in the proposed rule is addressed so that electronic prior authorization by non-Part D prescription drug plans is not impeded by the final rule.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
2nd Quarter, 2020
In Q2, MCDERMOTT WILL & EMERY LLP lobbied for Surescripts , earning $40,000. The report was filed on July 16, 2020.
Original Filing: 301189075.xml
Lobbying Issues
Efforts to advance interoperability and to ensure technological advances in electronic prescribing benefit patients, prescribers and others in the pharmacy services benefits in a timely way, including improving the process for updating the SCRIPT electronic prescribing standard to allow for both testing and for more expeditious adoption of updated electronic prescribing standards.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues/Technology
Lobbying Issues
Efforts to advance interoperability and to ensure technological advances in electronic prescribing benefit patients, prescribers and others in the pharmacy services benefits in a timely way, including improving the process for updating the SCRIPT electronic prescribing standard to allow for both testing and for more expeditious adoption of updated electronic prescribing standards.
Efforts to ensure timely implementation of the SUPPORT Act requirement for electronic prescribing of controlled substances in the Medicare Part D program beginning January 1, 2021.
Efforts to support CMSs proposed adoption of NCPDP SCRIPT Standard Version 2017071 for secure electronic prior authorization transactions for Part D-covered drugs and to ensure that problematic preamble language in the proposed rule is addressed so that electronic prior authorization by non-Part D prescription drug plans is not impeded by the final rule.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
1st Quarter, 2020
In Q1, MCDERMOTT WILL & EMERY LLP lobbied for Surescripts , earning $50,000. The report was filed on April 16, 2020.
Original Filing: 301168147.xml
Lobbying Issues
Efforts to advance interoperability and to ensure technological advances in electronic prescribing benefit patients, prescribers and others in the pharmacy services benefits in a timely way, including improving the process for updating the SCRIPT electronic prescribing standard to allow for both testing and for more expeditious adoption of updated electronic prescribing standards.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Technology
Lobbying Issues
Efforts to advance interoperability and to ensure technological advances in electronic prescribing benefit patients, prescribers and others in the pharmacy services benefits in a timely way, including improving the process for updating the SCRIPT electronic prescribing standard to allow for both testing and for more expeditious adoption of updated electronic prescribing standards. Efforts to ensure timely implementation of the SUPPORT Act requirement for electronic prescribing of controlled substances in the Medicare Part D program beginning January 1, 2021.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, MCDERMOTT WILL & EMERY LLP lobbied for Surescripts , earning $40,000. The report was filed on Jan. 13, 2020.
Original Filing: 301105071.xml
Lobbying Issues
Efforts to advance interoperability, including improving the process for updating the SCRIPT electronic prescribing standard, to allow for both piloting and for more timely adoption of updated electronic prescribing standards.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Technology/Medicaid
3rd Quarter, 2019
In Q3, MCDERMOTT WILL & EMERY LLP lobbied for Surescripts , earning $40,000. The report was filed on Oct. 17, 2019.
Original Filing: 301067350.xml
Lobbying Issues
Efforts to advance interoperability, including improving the process for updating the SCRIPT electronic prescribing standard, to allow for both piloting and for more timely adoption of updated electronic prescribing standards.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Technology/Medicaid
2nd Quarter, 2019
In Q2, MCDERMOTT WILL & EMERY LLP lobbied for Surescripts , earning $30,000. The report was filed on July 19, 2019.
Original Filing: 301051410.xml
Lobbying Issues
Efforts to advance interoperability, including improving the process for updating the SCRIPT electronic prescribing standard, to allow for both piloting and for more timely adoption of updated electronic prescribing standards.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Technology/Medicaid
1st Quarter, 2019
In Q1, MCDERMOTT WILL & EMERY LLP lobbied for Surescripts , earning $30,000. The report was filed on April 17, 2019.
Original Filing: 301026940.xml
Lobbying Issues
Efforts to advance interoperability, including improving the process for updating the SCRIPT electronic prescribing standard, to allow for both piloting and for more timely adoption of updated electronic prescribing standards.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Technology/Medicaid
4th Quarter, 2018
In Q4, MCDERMOTT WILL & EMERY LLP lobbied for Surescripts , earning $10,000. The report was filed on Jan. 18, 2019.
Original Filing: 301009144.xml
Lobbying Issues
Efforts to improve the process for updating the SCRIPT electronic prescribing standard, to allow for both piloting and for more timely adoption of updated electronic prescribing standards.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Technology/Medicaid
3rd Quarter, 2018
In Q3, MCDERMOTT WILL & EMERY LLP lobbied for Surescripts , earning $50,000. The report was filed on Oct. 19, 2018.
Original Filing: 300990289.xml
Lobbying Issues
Efforts to improve the process for updating the SCRIPT electronic prescribing standard, to allow for both piloting and for more timely adoption of updated electronic prescribing standards.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Technology/Medicaid
2nd Quarter, 2018
In Q2, MCDERMOTT WILL & EMERY LLP lobbied for Surescripts , earning $70,000. The report was filed on July 18, 2018.
Original Filing: 300968515.xml
Lobbying Issues
Efforts to improve the process for updating the SCRIPT electronic prescribing standard, to allow for both piloting and for more timely adoption of updated electronic prescribing standards.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Technology/Medicaid
1st Quarter, 2018
In Q1, MCDERMOTT WILL & EMERY LLP lobbied for Surescripts , earning $40,000. The report was filed on April 20, 2018.
Original Filing: 300956057.xml
Lobbying Issues
Efforts to improve the process for updating the electronic prescribing standard, to allow for both piloting and for more timely adoption of updated electronic prescribing standards.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Technology
4th Quarter, 2017
In Q4, MCDERMOTT WILL & EMERY LLP lobbied for Surescripts , earning $40,000. The report was filed on Jan. 19, 2018.
Original Filing: 300929116.xml
Lobbying Issues
Efforts to improve the process for updating the electronic prescribing standard, to allow for both piloting and for more timely adoption of updated electronic prescribing standards.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Technology
4th Quarter, 2017
McDermott Will & Emery LLP filed a lobbying registration on Dec. 20, 2017 to represent Surescripts, effective Nov. 17, 2017.
Original Filing: 300920537.xml
Issue(s) they said they’d lobby about: Efforts to improve the electronic prescribing standard, to allow for both piloting and for more timely adoption of updated electronic prescribing standards. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...